0305 Tenaya financing
BioCentury & Getty Images

Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

The company will also advance three heart disease platforms in parallel

Mar 6, 2021 | 1:41 AM GMT

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine

Read the full 615 word article

How to gain access

Continue reading with a
two-week free trial.